Last mentioned: Mar 10, 2026
Clinical Milestones
Anticipated updates on Phase 1/2 glioblastoma trial progress.
Clinical Milestones
Anticipated updates on Phase 1/2 trial progress for MT-125 in GBM.
BioFlorida Showcase
Cornerstone Session presentation on innovation in the regional ecosystem.
BioFlorida Showcase
Presentation in the Cornerstone Session: Innovation at BioFlorida.
BioFlorida Showcase
Cornerstone Session presentation on Innovation in South Florida.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
Investival Showcase
Participation in the South Florida - The Rising Life Science Hub event.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
Conference Invitations
Announced invitations to two major South Florida life sciences showcases.
Conference Announcement
Invited to present at two major South Florida life sciences events.
National Partnering
Presented at BioCom California Global Life Science Partnering Conference.
Partnering Circuit
Presented at BioCom California Global Life Science Partnering Conference.
National Engagement
Presented at BioCom California and BIO Investor Forum to engage global partners.
Myosin Therapeutics has been selected to present its novel nanomotor-dependency platform at two major South Florida life sciences conferences this March. The company is advancing MT-125, a first-in-class inhibitor currently in Phase 1/2 trials for glioblastoma, as it seeks to capitalize on South Florida's emergence as a biotechnology hub.
Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
Myosin Therapeutics has been selected to present its first-in-class nanomotor-dependency platform at two major South Florida life sciences conferences in March 2026. The company is advancing MT-125, a dual NMIIA/IIB inhibitor currently in Phase 1/2 trials for glioblastoma, targeting the physical mechanics of cancer cells to bypass traditional resistance.